Literature DB >> 12406221

Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis.

Michelle H Larsen1, Catherine Vilchèze, Laurent Kremer, Gurdyal S Besra, Linda Parsons, Max Salfinger, Leonid Heifets, Manzour H Hazbon, David Alland, James C Sacchettini, William R Jacobs.   

Abstract

The inhA and kasA genes of Mycobacterium tuberculosis have each been proposed to encode the primary target of the antibiotic isoniazid (INH). Previous studies investigating whether overexpressed inhA or kasA could confer resistance to INH yielded disparate results. In this work, multicopy plasmids expressing either inhA or kasA genes were transformed into M. smegmatis, M. bovis BCG and three different M. tuberculosis strains. The resulting transformants, as well as previously published M. tuberculosis strains with multicopy inhA or kasAB plasmids, were tested for their resistance to INH, ethionamide (ETH) or thiolactomycin (TLM). Mycobacteria containing inhA plasmids uniformly exhibited 20-fold or greater increased resistance to INH and 10-fold or greater increased resistance to ETH. In contrast, the kasA plasmid conferred no increased resistance to INH or ETH in any of the five strains, but it did confer resistance to thiolactomycin, a known KasA inhibitor. INH is known to increase the expression of kasA in INH-susceptible M. tuberculosis strains. Using molecular beacons, quantified inhA and kasA mRNA levels showed that increased inhA mRNA levels corre--lated with INH resistance, whereas kasA mRNA levels did not. In summary, analysis of strains harbouring inhA or kasA plasmids yielded the same conclusion: overexpressed inhA, but not kasA, confers INH and ETH resistance to M. smegmatis, M. bovis BCG and M. tuberculosis. Therefore, InhA is the primary target of action of INH and ETH in all three species.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406221     DOI: 10.1046/j.1365-2958.2002.03162.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  73 in total

1.  Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil.

Authors:  Rosilene Fressatti Cardoso; Robert C Cooksey; Glenn P Morlock; Patricia Barco; Leticia Cecon; Francisco Forestiero; Clarice Q F Leite; Daisy N Sato; Maria de Lourdes Shikama; Elsa M Mamizuka; Rosario D C Hirata; Mario H Hirata
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 2.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

3.  A novel mechanism of growth phase-dependent tolerance to isoniazid in mycobacteria.

Authors:  Makoto Niki; Mamiko Niki; Yoshitaka Tateishi; Yuriko Ozeki; Teruo Kirikae; Astrid Lewin; Yusuke Inoue; Makoto Matsumoto; John L Dahl; Hisashi Ogura; Kazuo Kobayashi; Sohkichi Matsumoto
Journal:  J Biol Chem       Date:  2012-05-30       Impact factor: 5.157

4.  Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.

Authors:  F Brossier; N Veziris; C Truffot-Pernot; V Jarlier; W Sougakoff
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

5.  New insight into the mechanism of action of and resistance to isoniazid: interaction of Mycobacterium tuberculosis enoyl-ACP reductase with INH-NADP.

Authors:  Argyrides Argyrou; Matthew W Vetting; John S Blanchard
Journal:  J Am Chem Soc       Date:  2007-07-18       Impact factor: 15.419

6.  Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping.

Authors:  Burkhard Springer; Romana C Calligaris-Maibach; Claudia Ritter; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2008-10-15       Impact factor: 5.948

7.  Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan.

Authors:  Chiyoji Abe; Ikuo Kobayashi; Satoshi Mitarai; Masako Wada; Yoshiko Kawabe; Tetsuya Takashima; Katsuhiro Suzuki; Li-Hwei Sng; Suxing Wang; Hla Hla Htay; Hideo Ogata
Journal:  J Clin Microbiol       Date:  2008-05-28       Impact factor: 5.948

8.  Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Manzour Hernando Hazbón; Michael Brimacombe; Miriam Bobadilla del Valle; Magali Cavatore; Marta Inírida Guerrero; Mandira Varma-Basil; Helen Billman-Jacobe; Caroline Lavender; Janet Fyfe; Lourdes García-García; Clara Inés León; Mridula Bose; Fernando Chaves; Megan Murray; Kathleen D Eisenach; José Sifuentes-Osornio; M Donald Cave; Alfredo Ponce de León; David Alland
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

9.  Requirements for nitric oxide generation from isoniazid activation in vitro and inhibition of mycobacterial respiration in vivo.

Authors:  Graham S Timmins; Sharon Master; Frank Rusnak; Vojo Deretic
Journal:  J Bacteriol       Date:  2004-08       Impact factor: 3.490

10.  Synthesis and biological evaluation of NAS-21 and NAS-91 analogues as potential inhibitors of the mycobacterial FAS-II dehydratase enzyme Rv0636.

Authors:  Veemal Bhowruth; Alistair K Brown; Gurdyal S Besra
Journal:  Microbiology (Reading)       Date:  2008-07       Impact factor: 2.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.